Alere continues pursuit of Axis-Shield with shareholder offer
This article was originally published in Clinica
Executive Summary
In its latest effort to takeover Axis-Shield, Alere has posted an offer document to the company's shareholders. As before, the diagnostics giant is offering 460p per share, which values Axis-Shield at £230m ($375m) in total. In response, Axis-Shield's board, which has already twice rebuffed Alere, issued a statement maintaining that the bid fundamentally undervalues the company and its future prospects. The company said it will write to shareholders setting out its position on Alere's offer by 25 August. Alere has been steadily building its stake in the Anglo-Nordic IVD firm in a bid to put pressure on Axis-Shield's board to agree to a takeover. Alere currently holds 9.09% of the company, making it the second-biggest shareholder after Legal and General (www.clinica.co.uk, 10 August 2011).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.